BRCA2‐positive lung adenocarcinoma treated with olaparib: A case reportdoi:10.1002/rcr2.1317Motohashi, TakumiIsobe, KazutoshiYoshizawa, TakahiroUsui, YusukeShimizu, HiroshigeSekiya, MuneyukiMiyoshi, ShionNakamura, YasuhikoUrabe, NaohisaSakamoto, Susumu...
Clinical and Pathological Characteristics of BRCA2 Positive Breast Cancer in Egyptian Female PatientsMutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. Early age at onset is generally considered an indicator of genetic susceptibility to breast cancer. We determined ...
用途范围 Positive Control; Immunogen; SDS-PAGE; WB. 如果需要有生物活性的蛋白,请参见活性蛋白。 包装规格 0.5kg 来源 原核表达 片段与标签 Lys2308~His2537 with N-terminal His Tag 性状 冻干粉 宿主 E.coli 可售卖地 北京;天津;河北;山西;内蒙古;辽宁;吉林;黑龙江;上海;江苏;浙江;安徽;福建;...
[11] Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer:a report from the Australian Ovarian Cancer Study Group [ J]...
1.Byrski T, Huzarski T, Dent R, et al:Pathologic complete response to neoadjuvant cisplatin inBRCA1 positive breast cancer patients. Breast Cancer Res Treat 147:401-5, 2014 2.KaufmanB,ShapiraFrommer R, Schmutzler RK, et al: Olaparib m...
Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer DOI: 10.4236/abcr.2013.23010, PP. 56-59 Grazia Artioli, Giuseppe Azzarello, Fabrizio Meggiolaro, Jacopo Wabersich, Lucia Borgato, Mario Bari Keywords: BRCA 2, Breast Cancer, DNA, Cisplati...
Gains in LE are consistently lower for women with node-positive disease than for women with node-negative disease. The worse the prognosis of the primary breast cancer, the lower the likelihood a woman will survive to reap the benefits of secondary cancer prevention. Similarly, the potential bene...
Applications: Positive Control; Immunogen; SDS-PAGE; WB. (May be suitable for use in other assays to be determined by the end user.) Predicted isoelectric point: 9.7 Predicted Molecular Mass: 29.9kDa Accurate Molecular Mass: 32kDa as determined by SDS-PAGE reducing conditions. ...
应用Positive Control; Immunogen; SDS-PAGE; WB. 如果需要有生物活性的蛋白,请参见活性蛋白 序列 用法 Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex. 储存 避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
Gonzalez-Carmona MA. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Front Oncol. 2022 Jul 25;12:933943. doi: 10.3389/fonc.2022.933943. PMID: 35957899; PMCID: PMC...